Saniona, a research and development company, engages in the development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The Company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trial to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of metabolic diseases and prader-wills syndromes; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase I clinical trial for ataxia/tremor.